Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Array BioPharma has initiated dosing cancer patients in a phase I clinical trial for its targeted small molecule anticancer drug ARRY-334543.
Subscribe to our email newsletter
The open-label, dose-escalation trial is designed to evaluate tolerability and pharmacokinetics of the drug following oral administration to patients with advanced cancer. In addition, the trial is designed to examine indicators of therapeutic activity in these patients.
The drug has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.
ARRY-334543 is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients.
“Advancing ARRY-334543 into clinical trials is a significant achievement for Array and further demonstrates our ability to invent novel therapies for cancer patients,” said Dr Kevin Koch, president and chief scientific officer.